Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/20/2005WO2005072268A3 Treatment of degeneraative cartilage conditions in a mammal with glycosidase inhibitors
10/20/2005WO2005070919A8 N-type calcium channel blockers
10/20/2005WO2005066143A3 Benzo[d]isoxazol-3-ol daao inhibitors
10/20/2005WO2005066129A3 Bis-pyridino containing compounds for use in the treatment of cns pathologies
10/20/2005WO2005066116A8 Disubstituted chalcone oximes as selective agonists of rarϝ retinoid receptors
10/20/2005WO2005065664A8 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
10/20/2005WO2005061450A3 Hiv protease inhibiting sulfonamides
10/20/2005WO2005060972A3 Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection
10/20/2005WO2005058845A3 Novel glucagon antagonists/inverse agonists
10/20/2005WO2005055950A3 Glycopegylated factor ix
10/20/2005WO2005055922A3 Use of benzothiopenes to treat and prevent prostate cancer
10/20/2005WO2005053660A3 Pharmaceutical compositions comprising danazol
10/20/2005WO2005051362A3 Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
10/20/2005WO2005049561A3 Processes for preparing novel methylene blue derivative
10/20/2005WO2005046590A3 Methods for synthesizing quinolinone compounds
10/20/2005WO2005044191A3 Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
10/20/2005WO2005039497A3 Methods and compositions comprising thalidomide for treatment of fibromyalgia
10/20/2005WO2005035525A3 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/20/2005WO2005030794B1 Hemiasterlin derivatives and uses thereof
10/20/2005WO2005025535A3 Methods for preparing pharmaceutical compositions
10/20/2005WO2005020923A3 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
10/20/2005WO2005018530A3 Penetrating pharmaceutical foam
10/20/2005WO2005011638A3 Methods for the stabilization of atorvastatin
10/20/2005WO2005009391A3 Antibiotic compound
10/20/2005WO2005009370A3 Beta-carboline compounds and analogues thereof and their use as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
10/20/2005WO2005004798A3 Methods for treating lentivirus infections
10/20/2005WO2004103389A3 Means for preventing and treating cellular death and their biological applications
10/20/2005WO2004103289A3 Driverse thyroid hormone receptor antagonists and uses thereof
10/20/2005WO2004096147A3 Oxo-pyrimidine compounds
10/20/2005WO2004076410A8 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
10/20/2005WO2004071460A3 Cyclic derivatives as modulators of chemokine receptor activity
10/20/2005WO2004071398A9 Pharmaceutical patch
10/20/2005WO2004064785A3 Cancer therapy sensitizer
10/20/2005WO2004028481A3 Nucleoside derivatives for treating hepatitis c virus infection
10/20/2005WO2003106413A3 Process for the preparation of oxazolidinones and method of use thereof
10/20/2005WO2003002094A8 Enhanced pharmacokinetic profile of hydrophobic substances
10/20/2005WO2002097033A3 Antibodies that immunospecifically bind to trail receptors
10/20/2005US20050235367 Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
10/20/2005US20050234399 System for perfusion management
10/20/2005US20050234398 System with a reservoir for perfusion management
10/20/2005US20050234393 Telescoping perfusion management system
10/20/2005US20050234265 2-aminomethyl-5-tert-butyl-3-phenylphenol; antimalaria; used against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234241 Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (montelukast) and its pharmaceutically acceptable salts
10/20/2005US20050234235 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
10/20/2005US20050234233 Cephalosporins
10/20/2005US20050234227 Ribosome structure and protein synthesis inhibitors
10/20/2005US20050234222 Polypeptide comprising at least one alpha-helix having synthetically attached thereto a plurality of therapeutic or diagnostic moieties
10/20/2005US20050234135 co-crystal with acetic acid that inhibit the function(s) of anti-apoptotic Bcl-2 family proteins will kill cancer cells or supporting cells outright and/or render such cells as a population more susceptible; kits; instructions
10/20/2005US20050234134 Betamimetics with a prolonged duration of activity, processes for preparing them, and their use as pharmaceutical compositions
10/20/2005US20050234133 Use of fingolimod or salt
10/20/2005US20050234131 Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof
10/20/2005US20050234130 Medicament for therapeutic treatment of vascular disease
10/20/2005US20050234129 Salts of nateglinide
10/20/2005US20050234128 Process for preparing fluoroleucine alkyl esters
10/20/2005US20050234127 Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field
10/20/2005US20050234126 Amide derivatives as inhibitors of the enzymatic activity of renin
10/20/2005US20050234124 Carboxyalkylether-ACAT inhibitor combinations
10/20/2005US20050234123 Process
10/20/2005US20050234122 Prevention of and countermeasures against viral infection
10/20/2005US20050234121 coating formulations and polymers that utilize a dioxanone containing composition or fatty acid derivative
10/20/2005US20050234120 For example, 5-acetyl-3-{[4-(diethylaminomethyl)-phenylamino]-phenyl-methylidene}-2-indolinone; for treatment of diabetes mellitus, diabetes associated disorders such as diabetic neuropathy, degenerative neurological diseases such as Alzheimer's disease, stroke, neurotraumatic injuries, bipolar disorders
10/20/2005US20050234119 Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234117 and geranylgeranyltransferase inhibitor; 3-chloromethyl-4-cyanobenzyl-5 methyl triazole; antitumor agents; prevent membrane attachment of protein p21ras and block aberrant growth of ras-transformed tumors; capable to inhibit prenylation of Ras proteins, both at enzymatic and cellular level
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234115 Dosage forms and methods of treatment using VEGFR inhibitors
10/20/2005US20050234114 Encapsulated with macromolecules, bile salts
10/20/2005US20050234113 Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
10/20/2005US20050234111 D-homo-17-chlor-16(17)-ene steroids
10/20/2005US20050234108 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
10/20/2005US20050234107 Use of diuretics for treating swellings
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234104 Dabigatran etexilate mesylate polymorph, crystalline form of a prodrug used for post-operative prophylaxis of deep vein thrombosis and the prevention of a stroke; stability; solubility; reproduciblity; hydrophobic; pharmacological potency; low amorphization during grinding and compression
10/20/2005US20050234103 Crystalline forms of rabeprazole sodium
10/20/2005US20050234102 Inhibiting the proteolytic activity of cathepsin S, comprising exposing cathepsin S to compounds such as 1-[4-(5-Chloro-1H-indol-3-yl)-piperidin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol
10/20/2005US20050234100 Insulin resistance as new action of loperamide
10/20/2005US20050234099 Microsomal triglyceride transfer protein (MTP) inhibitor (S)-2-[(4'-Isopropoxybiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid {[(4-fluoro-benzyl)methylcarbamoyl]phenylmethyl}amide; treating obesity
10/20/2005US20050234097 Compounds useful for the treatment of diseases
10/20/2005US20050234095 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
10/20/2005US20050234094 Inhibition of protein kinases with piridinylimidazoles
10/20/2005US20050234093 Treatment of depression and other affective disorders
10/20/2005US20050234092 Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
10/20/2005US20050234091 Antiinflammatory agents; antiallergens; antiproliferative agents; 4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-4H-thieno[3,2-b]pyridin-7-one derivatives
10/20/2005US20050234090 Modulators of chemokine receptor activity
10/20/2005US20050234089 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
10/20/2005US20050234088 Urea substituted imidazoquinoline ethers
10/20/2005US20050234086 Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
10/20/2005US20050234085 1-methyl-3 beta -hydroxymethyl-6-methoxy-1,2,3,4,4a alpha ,5,10, 10a beta -octahydrobenzo[q]quinoline; decrease on the intraocular pressure; glaucoma and myopia; excellent tolerability, and a long duration of action
10/20/2005US20050234083 Diamino-pyrimidines and their use as angiogenesis inhibitors
10/20/2005US20050234082 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234080 Mitotic kinesin inhibitors
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234078 Assay method for achieving a range of 6-thioguanine in a subject: determining a level of 6-thioguanine and recommending that a subsequent dose be increased
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234075 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
10/20/2005US20050234073 in mammals by administering drugs which inhibits the expression or activity of microsomal triglyceride transfer proteins; antiinflammatory agents; enzyme inhibitors; reducing direct transfer of phosphatides or lipid to cd antigens
10/20/2005US20050234072 e.g., N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; used to hydrate mucosal surfaces; are absorbed less rapidly, thus have a prolonged pharmacodynamic half-life
1 ... 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 4509 4510 4511 4512 4513 4514 4515 4516 ... 7860